Effect of Panax Ginseng on the Cognitive Performance in Alzheimer’s Disease

This study has been completed.
Information provided by:
Seoul National University Hospital
ClinicalTrials.gov Identifier:
First received: October 22, 2006
Last updated: NA
Last verified: October 2006
History: No changes posted
We investigate the clinical efficacy of Panax ginseng in Alzheimer’s disease (AD).

Condition Intervention Phase
Alzheimer's Disease
Memory Decline
Drug: Panax Ginseng
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • Cognitive performances monitored by MMSE and Alzheimer’s disease assessment scales.
  • Biomarkers including hematopoietic progenitor cell count.

Study Start Date: April 2004
Estimated Study Completion Date: October 2005
Detailed Description:

Alzheimer’s disease (AD) is characterized by a progressive decline of memory and intellectual abilities, interfering activity in daily living, the overall quality of life, and ultimately leads to death. Although pharmacologic treatments are currently approved for treating mild- to moderate AD using acetylcholinesterase inhibitors (ACEI) or memantine, the NMDA antagonist, for the advanced stage of AD, the therapeutic efficacies need to be further improved.

For millennia, ginseng or its components have been used to treat medical conditions, and the pharmacologic effects have been demonstrated in cardiovascular, endocrine and immune system (Attele et al., 1999). In means of memory and learning, a number of studies suggested that ginseng can attenuate learning deficits of damaged or ageing brains in rodent models (Kennedy et al., 2003; Zhao and McDaniel, 1998; Nitta et al., 1995). In studies with human healthy participants, correspondently, both acute and chronic dosage of ginseng increased the cognitive performance (Kennedy et al., 2001; Kennedy et al., 2003; D’Angelo et al., 1986; Sorensen and Sonne, 1996).

In this study, we we will investigate the contribution of ginseng treatment in increasing the cognitive improvement of AD patients. In addition, we will test various bio-markers and hematopoietic progenitor cell count in those included patients using their blood samples. Patients with AD as well as memory decline will be included


Ages Eligible for Study:   40 Years to 83 Years
Genders Eligible for Study:   Female

Inclusion Criteria:

  • Alzheimer's disease

Exclusion Criteria:

  • other neurologic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00391833

Sponsors and Collaborators
Seoul National University Hospital
Study Chair: Manho Kim, MD, PhD Department of Neurology, Seoul National University Hospital
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00391833     History of Changes
Other Study ID Numbers: ginseng-AD 
Study First Received: October 22, 2006
Last Updated: October 22, 2006
Health Authority: Korea: Food and Drug Administration

Keywords provided by Seoul National University Hospital:
Alzheimer's disease, Ginseng, CD34

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on May 05, 2016